2 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 2 | Recruiting 2 |
Follow Adenocarcinoma of Colon: new trials by email Literature Review of Adenocarcinoma of Colon trials Research Report on Adenocarcinoma of Colon
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer EB-DUO-CAR-NK-CEA/GCC (IV) - Colorectal Cancer Metastatic, Adenocarcinoma of Colon | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 48 | 2026-02-01 | 2026-03-10 |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
Colonic Neoplasms (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasm, Residual (1) · Rectal Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Breast Diseases (1) · Carcinoma (1) · Colorectal Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Neoplastic Processes (1)
ALX148 (1) · tucatinib (1) · zanidatamab (1)
Beijing Biotech (1) · QuantumLeap Healthcare Collaborative (1)
China (1) · United States (1)